Jun 01, 2020
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
May 12, 2020
Minerva Surgical® Announces Acquisition Closing of Boston Scientific Intrauterine Health Products
Jan 27, 2020
Heavy Menstrual Bleeding (HMB) Study 2020: Epidemiology, Trends, Treatment, Unmet Needs, Marketed & Emerging Drugs, Case Reports, Market Outlook to 2028
Aug 05, 2019
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Jul 11, 2019
Midwest Institute for Non-Surgical Therapy Opens Unique Fibroid Center: Innovative Treatment of Large Fibroids Without Surgery
May 06, 2019
Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.
Apr 02, 2019
Channel Medsystems® Receives U.S. FDA Approval of the Cerene® Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding
Mar 29, 2019
Insights into the World Endometrial Ablation Devices Market, 2019: Forecast to 2026
Feb 07, 2019
Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018
Nov 16, 2018
Women's Excellence in Rochester, Michigan Now Offers Treatment Plans for Women with Pelvic Pain
Oct 08, 2018
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
Oct 02, 2018
Octapharma USA Sponsors The Female Factor Women's Retreat in Monterey